JP2014129395A5 - - Google Patents

Download PDF

Info

Publication number
JP2014129395A5
JP2014129395A5 JP2014040570A JP2014040570A JP2014129395A5 JP 2014129395 A5 JP2014129395 A5 JP 2014129395A5 JP 2014040570 A JP2014040570 A JP 2014040570A JP 2014040570 A JP2014040570 A JP 2014040570A JP 2014129395 A5 JP2014129395 A5 JP 2014129395A5
Authority
JP
Japan
Prior art keywords
moiety
ddd
pegylated
therapeutic agent
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014040570A
Other languages
English (en)
Japanese (ja)
Other versions
JP5779789B2 (ja
JP2014129395A (ja
Filing date
Publication date
Priority claimed from US11/925,408 external-priority patent/US7666400B2/en
Application filed filed Critical
Publication of JP2014129395A publication Critical patent/JP2014129395A/ja
Publication of JP2014129395A5 publication Critical patent/JP2014129395A5/ja
Application granted granted Critical
Publication of JP5779789B2 publication Critical patent/JP5779789B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014040570A 2007-10-26 2014-03-03 ドック・ロック（ｄｎｌ）技術によるｐｅｇ化 Active JP5779789B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/925,408 US7666400B2 (en) 2005-04-06 2007-10-26 PEGylation by the dock and lock (DNL) technique
US11/925,408 2007-10-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010531272A Division JP5577558B2 (ja) 2007-10-26 2008-10-24 ドック・ロック（ｄｎｌ）技術によるｐｅｇ化

Publications (3)

Publication Number Publication Date
JP2014129395A JP2014129395A (ja) 2014-07-10
JP2014129395A5 true JP2014129395A5 (cg-RX-API-DMAC7.html) 2014-08-21
JP5779789B2 JP5779789B2 (ja) 2015-09-16

Family

ID=40580038

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010531272A Active JP5577558B2 (ja) 2007-10-26 2008-10-24 ドック・ロック（ｄｎｌ）技術によるｐｅｇ化
JP2014040570A Active JP5779789B2 (ja) 2007-10-26 2014-03-03 ドック・ロック（ｄｎｌ）技術によるｐｅｇ化

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010531272A Active JP5577558B2 (ja) 2007-10-26 2008-10-24 ドック・ロック（ｄｎｌ）技術によるｐｅｇ化

Country Status (10)

Country Link
US (5) US7666400B2 (cg-RX-API-DMAC7.html)
EP (1) EP2197468B1 (cg-RX-API-DMAC7.html)
JP (2) JP5577558B2 (cg-RX-API-DMAC7.html)
KR (1) KR101583388B1 (cg-RX-API-DMAC7.html)
CN (1) CN101951939B (cg-RX-API-DMAC7.html)
AU (1) AU2008316741B9 (cg-RX-API-DMAC7.html)
CA (1) CA2696160C (cg-RX-API-DMAC7.html)
IL (1) IL204066A (cg-RX-API-DMAC7.html)
MX (1) MX2010004547A (cg-RX-API-DMAC7.html)
WO (1) WO2009055653A1 (cg-RX-API-DMAC7.html)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
ATE516820T1 (de) 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US7906118B2 (en) * 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
US7901680B2 (en) * 2005-10-19 2011-03-08 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) vaccines for cancer therapy
US8003111B2 (en) * 2005-04-06 2011-08-23 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US20110064754A1 (en) * 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8034352B2 (en) * 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US8491914B2 (en) 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
WO2006094192A2 (en) 2005-03-03 2006-09-08 Immunomedics, Inc. Humanized l243 antibodies
US8481041B2 (en) 2005-04-06 2013-07-09 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8158129B2 (en) 2005-04-06 2012-04-17 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
AU2006232920B2 (en) * 2005-04-06 2011-09-29 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8067006B2 (en) * 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US9623115B2 (en) 2005-04-06 2017-04-18 Ibc Pharmaceuticals, Inc. Dock-and-Lock (DNL) Complexes for Disease Therapy
US9931413B2 (en) 2005-04-06 2018-04-03 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US9862770B2 (en) 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US20100226884A1 (en) * 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
AU2011292178B8 (en) * 2006-12-05 2016-01-21 Ibc Pharmaceuticals, Inc. Compositions and methods of use comprising combinations of anti-CD74 antibodies with a therapeutic agent. the therapeutic agent may be attached to the anti-CD74 antibody or may be separately administered, either before, simultaneously with or after the anti-CD74 antibody
CA2675014C (en) * 2007-01-17 2016-03-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
AU2008275911A1 (en) * 2007-07-19 2009-01-22 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University Self- anchoring MEMS intrafascicular neural electrode
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
US9272029B2 (en) 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
US8691205B2 (en) 2008-12-17 2014-04-08 Merck Sharp & Dohme Corporation Mono- and di-PEG IL-10 production; and uses
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
JP5843357B2 (ja) 2009-02-03 2016-01-13 アムニクス オペレーティング インコーポレイテッド 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
NZ596778A (en) * 2009-06-08 2013-11-29 Amunix Operating Inc Glucose-regulating polypeptides and methods of making and using same
JP2013502458A (ja) 2009-08-24 2013-01-24 アムニクス オペレーティング インコーポレイテッド 凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
IN2012DN01662A (cg-RX-API-DMAC7.html) * 2009-08-31 2015-06-05 Immunomedics Inc
EP2473186A4 (en) * 2009-08-31 2013-07-10 Ibc Pharmaceuticals Inc BIS SPECIFIC IMMUNOZYTOKIN DOCK-AND-LOCK COMPLEXES AND THERAPEUTIC USE THEREOF
EP3009455A1 (en) * 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
AU2010315432A1 (en) * 2009-11-05 2012-04-12 Center For Molecular Medicine And Immunology Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
WO2011068845A1 (en) 2009-12-02 2011-06-09 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
AU2010328136B2 (en) * 2009-12-09 2016-02-25 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
CN102665757A (zh) * 2009-12-09 2012-09-12 免疫医疗公司 通过双特异性抗体预靶向的用于细胞毒性药物的递送系统
JP5798125B2 (ja) * 2009-12-15 2015-10-21 チェ，ムヒョン 単量体に結合特異性がある結合体の反復鎖と多数単量体の複合体内での架橋結合の生成増加を通じた二量体及び多量体の生産方法
US10822396B2 (en) 2009-12-15 2020-11-03 MuHyeon CHOE Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
AU2011323354B2 (en) * 2010-11-03 2014-07-31 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
US9140698B2 (en) 2011-04-06 2015-09-22 The Board Of Regents Of The University Of Texas System Modulating bacterial MAM polypeptides in pathogenic disease
CN103501825B (zh) 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
US20130101664A1 (en) 2011-08-18 2013-04-25 Donald W. Kufe Muc1 ligand traps for use in treating cancers
WO2013036130A1 (en) 2011-09-09 2013-03-14 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
CA2855566A1 (en) * 2011-12-02 2013-06-06 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
MX369862B (es) 2012-02-15 2019-11-25 Bioverativ Therapeutics Inc Composiciones del factor viii y metodos para hacerlas y usarlas.
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
AU2013226090B2 (en) 2012-02-27 2018-03-08 Amunix Operating Inc. XTEN conjugate compositions and methods of making same
ES2672974T3 (es) 2012-06-01 2018-06-19 Ibc Pharmaceuticals, Inc. Complejos multiméricos con estabilidad in vivo, farmacocinética y eficacia mejoradas
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US10131712B2 (en) 2012-08-14 2018-11-20 Ibc Pharmaceuticals, Inc. Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
US9315567B2 (en) 2012-08-14 2016-04-19 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
KR101358330B1 (ko) 2012-09-26 2014-02-12 현대모비스 주식회사 차속 제어 장치, 이를 포함하는 차속 제어 시스템 및 그 제어 방법
CN104837508A (zh) 2012-12-13 2015-08-12 免疫医疗公司 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量
WO2014164394A1 (en) 2013-03-11 2014-10-09 Dana-Farber Cancer Institute, Inc. Combination anti-her2 cancer therapy using muc1 peptides and chemotherapeutics
AU2014254019B2 (en) * 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
HK1226308A1 (zh) 2013-08-30 2017-09-29 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
WO2015065987A1 (en) 2013-11-01 2015-05-07 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
BR112016010166A2 (pt) 2013-11-11 2017-12-05 Armo Biosciences Inc métodos para usar interleucina-10 para tratar doenças e distúrbios
KR20160102210A (ko) 2013-12-27 2016-08-29 노버스 인터내쇼날 인코포레이티드 에톡시화 계면활성제
KR20150080417A (ko) * 2013-12-30 2015-07-09 경희대학교 산학협력단 링커를 통해 연결된 동일한 표적 물질에 결합하는 항체 및 앱타머를 포함하는 집게 분자 및 이의 용도
ES2978993T3 (es) 2014-02-21 2024-09-23 Ibc Pharmaceuticals Inc Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
EP3110445A4 (en) 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
PL3204018T3 (pl) 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
CA2963989A1 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20170125839A (ko) * 2015-03-11 2017-11-15 넥타르 테라퓨틱스 Ｉｌ-7 부분 및 중합체의 접합체
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
EP3303370A4 (en) 2015-05-28 2019-03-13 Immunomedics, Inc. T20-CONSTRUCTS FOR THERAPY AND / OR VACCINES AGAINST HIV (HUMAN IMMUNODEFICIENCY VIRUS)
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
CN108025040A (zh) 2015-08-25 2018-05-11 阿尔莫生物科技股份有限公司 使用白介素-10治疗疾病和病症的方法
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
CA2998393A1 (en) 2015-09-11 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Biologically relevant orthogonal cytokine/receptor pairs
US10669338B2 (en) 2016-06-17 2020-06-02 Immunomedics, Inc. Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
US12158399B2 (en) 2016-08-05 2024-12-03 Duke University CaMKK2 inhibitor compositions and methods of using the same
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
CN107118269B (zh) * 2017-06-05 2020-12-01 北京交通大学 一种重组人il-24蛋白的peg修饰方法
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
CN112004826B (zh) 2018-02-05 2024-06-14 自由大学基金会 反向激动性抗us28抗体
WO2019183131A1 (en) 2018-03-19 2019-09-26 Bioventures, Llc Periostin antibodies and methods of using the same
LT3793588T (lt) 2018-05-18 2025-06-25 Bioverativ Therapeutics Inc. Hemofilijos a gydymo būdai
WO2019227022A1 (en) 2018-05-25 2019-11-28 Bioventures, Llc Myxoma virus compositions and methods of use
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2020106880A1 (en) 2018-11-20 2020-05-28 Bioventures, Llc Cells for the production of viruses and methods of using the same
JP7644087B2 (ja) 2019-07-26 2025-03-11 ヴァンダービルト ユニバーシティ エンテロウイルスｄ６８に対するヒトモノクローナル抗体
JP2023519105A (ja) 2020-02-11 2023-05-10 ヴァンダービルト ユニバーシティ 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）に対するヒトモノクローナル抗体
EP4045533B1 (en) 2020-03-26 2023-11-15 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541435A (en) 1975-02-04 1979-02-28 Searle & Co Immunological materials
NL8501219A (nl) 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic Immunologisch complex, de bereiding en toepassing daarvan.
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US20030198956A1 (en) 2002-02-21 2003-10-23 Lee Makowski Staged assembly of nanostructures
US20040018587A1 (en) 1994-10-13 2004-01-29 Lee Makowski Nanostructures containing antibody assembly units
US5871945A (en) 1994-11-23 1999-02-16 Icos Corporation Modulators of anchoring protein function
AU3908597A (en) * 1996-08-02 1998-02-25 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US6756039B1 (en) 1999-05-10 2004-06-29 The Regents Of The University Of California Self assembling proteins
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
EP1200479B1 (en) * 1999-08-09 2006-02-01 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US7060506B2 (en) 2000-01-31 2006-06-13 Cyclacel, Ltd. Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides
US6524854B1 (en) 2001-09-11 2003-02-25 Isis Pharmaceuticals, Inc. Antisense inhibition of PKA regulatory subunit RII alpha expression
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US8491896B2 (en) * 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
WO2003093296A2 (en) * 2002-05-03 2003-11-13 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
US7906118B2 (en) 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
GEP20084486B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
EP1618181B1 (en) 2003-04-22 2014-10-15 IBC Pharmaceuticals Polyvalent protein complex
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
US7901680B2 (en) * 2005-10-19 2011-03-08 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) vaccines for cancer therapy
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8034352B2 (en) * 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US20110064754A1 (en) 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
US8003111B2 (en) * 2005-04-06 2011-08-23 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
US8491914B2 (en) 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US7608425B2 (en) 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
WO2006094192A2 (en) 2005-03-03 2006-09-08 Immunomedics, Inc. Humanized l243 antibodies
US8067006B2 (en) * 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US9623115B2 (en) 2005-04-06 2017-04-18 Ibc Pharmaceuticals, Inc. Dock-and-Lock (DNL) Complexes for Disease Therapy
AU2006232920B2 (en) 2005-04-06 2011-09-29 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US8481041B2 (en) 2005-04-06 2013-07-09 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
US20120276100A1 (en) 2005-04-06 2012-11-01 Ibc Pharmaceuticals, Inc. Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
AU2006232310B9 (en) 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
US8158129B2 (en) 2005-04-06 2012-04-17 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
JP5231231B2 (ja) 2005-10-19 2013-07-10 アイビーシー・ファーマシューティカルズ・インコーポレーテッド 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用
KR101410521B1 (ko) 2005-12-16 2014-06-20 아이비씨 파마슈티컬스, 인코퍼레이티드 다가 면역글로불린-계 생동성 어셈블리들
CA2651285C (en) 2006-05-15 2014-08-19 Immunomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
BRPI0716744A2 (pt) 2006-09-14 2016-10-04 Human Genome Sciences Inc proteínas de fusão de albumina

Similar Documents

Publication Publication Date Title
JP2014129395A5 (cg-RX-API-DMAC7.html)
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
EP4303237A3 (en) Cytotoxicity-inducing therapeutic agent
WO2018098269A3 (en) Peptide-containing linkers for antibody-drug conjugates
EP1924282A4 (en) IMMUNIZATION OF AVIANES BY ADMINISTRATION OF NON-REPLICATED VACCINES
JP2017048194A5 (cg-RX-API-DMAC7.html)
JP2017509586A5 (cg-RX-API-DMAC7.html)
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
IL203869A (en) Method of Preparing a Containing a Virus or Antigen Antigen, Various Aspects Related to This Method, Uses of a Method and Vaccination of a Split Virus Prepared by This Method
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
BR112012016569A2 (pt) sistema de travamento mecânico para painéis de assoalho
IN2012DN00640A (cg-RX-API-DMAC7.html)
JP2015529678A5 (cg-RX-API-DMAC7.html)
DK2707393T3 (da) Fusionsproteiner og kombinationsvacciner omfattende haemoph-ilus influenzae-protein e og pilin a
EP3210625A3 (en) Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
JP2016512425A5 (cg-RX-API-DMAC7.html)
JP2012255007A5 (cg-RX-API-DMAC7.html)
SMT201400152B (it) Preparazione ed applicazioni terapeutiche di (2S,3R)-N-2-((3-piridinil)metil)-1-azabiciclo[2.2.2]ott-3-il)-3,5-difluorobenzammide
WO2015052543A3 (en) Malaria vaccination
JP2012505657A5 (cg-RX-API-DMAC7.html)
JP2013510169A5 (cg-RX-API-DMAC7.html)
WO2006115843A3 (en) Nipah virus vaccines
WO2011143469A8 (en) Therapeutic regimens
WO2009080715A3 (en) Vaccines for malaria
EP2190979A4 (en) IMPROVEMENT OF TRANSGENEXPRESSION OF VIRUS-BASED VACCINE VACCINORS BY EXPRESSION OF TYPE I INTERFERON ANSWER TYPE-I SUPPRESSORS